TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The investigational Lyme disease vaccine LB6V reduced cases in a phase III trial, but its main analysis did not meet the trial’s predefined statistical success threshold. A modified intent-to-treat analysis narrowly cleared that threshold, while protection appeared to decline by the third season after vaccination.
An investigational Lyme disease vaccine, LB6V, narrowly missed its predefined statistical success threshold in the main analysis of a phase III trial, despite an estimated 73.2% vaccine efficacy. A modified intent-to-treat analysis produced a slightly higher estimate that cleared the threshold, leaving the late-stage result mixed as researchers consider whether the vaccine could help prevent Lyme disease.
Among participants aged 5 and older in the evaluable population, four LB6V recipients and 15 placebo recipients developed Lyme disease after the four-dose regimen. The resulting efficacy estimate was 73.2%, with a 95% confidence interval of 15.8% to 93.5%. The trial’s predefined success requirement was that the lower end of the confidence interval exceed 20%, so this analysis did not meet it.
In a modified intent-to-treat analysis, efficacy was estimated at 74.8%, with a 95% confidence interval of 21.7% to 93.9%, just above the prespecified threshold. Paul Auwaerter, MD, of Johns Hopkins University School of Medicine, presented the findings at the IDWeek annual meeting. The difference between the analyses matters: the result that narrowly met the benchmark came from a modified population, while the evaluable-population analysis did not.
The placebo-controlled VALOR trial enrolled about 9,400 people at elevated risk in the United States, Canada and five European countries. Participants received vaccine or placebo at baseline, two months, about five to nine months, and around 18 months. The study followed participants across three Lyme disease seasons from 2022 through 2025. Its primary efficacy endpoint assessed cases beginning 28 days after dose four and continuing through the end of the Lyme disease season.
Adverse events were reported by 58.8% of vaccine recipients and 52.6% of placebo recipients. Treatment-related events leading to withdrawal occurred in 0.3% and 0.1%, respectively. Fatigue, headache, muscle and joint pain, as well as injection-site pain, redness and swelling, were more common among vaccine recipients. Newly diagnosed chronic medical conditions were reported at similar rates: 9.6% in the vaccine group and 9.5% in the placebo group.
A Mixed Result for Lyme Prevention
The findings matter because no Lyme disease vaccine is currently available for people in the United States, despite the disease’s substantial health burden. The source report says more than 80,000 cases are reported to the CDC annually, while an estimated 476,000 people are treated each year. Lyme disease can cause fever, headache, fatigue and a characteristic rash; untreated infection can spread to joints, the heart and nervous system.
LB6V’s efficacy estimate points to possible protection, but the primary analysis missed the trial’s statistical cutoff. That distinction prevents the results from being described as a clear phase III success. The modified analysis offers a more favorable reading, but does not erase the miss in the evaluable population. Regulators and researchers will need to assess the full results, including the analysis populations, duration of protection and safety profile, before the candidate’s prospects are clear.
Products Worth Considering
Oura Ring 4 Smart Ring – Silver – Size 8
Hyperice Hypervolt 3 Percussion Massage Gun with Heated Head and Premium Carry Case
Philips Sonicare DiamondClean 9500 Electric Toothbrush with 3 Brush Heads – Black
As an affiliate, we earn on qualifying purchases.
Four Doses, Then Waning Protection
LB6V, previously known as VLA15, is an adjuvanted protein-subunit vaccine designed to cover six serotypes across four Borrelia species common in Europe and North America. The approach aims to prompt vaccinated people to pass antibodies to ticks as they bite; those antibodies can inhibit Borrelia burgdorferi in the tick and prevent transmission. Earlier phase II trials reported immune responses and an apparently acceptable safety profile, according to the source report.
The trial’s season-by-season findings raise a separate question about how long protection lasts. Estimated efficacy fell from 73.2% in the second season after the four-dose vaccination schedule to 18.6% in the third season. The third-season confidence interval was wide, from -220.0% to 80.4%, so that estimate is highly uncertain. Antibody geometric mean titers against B. burgdorferi outer surface protein A serotype 1 also declined, from 1,100.3 to 35.7 over the same seasons.
Lyme disease vaccine development has a history that may shape public attention. The FDA approved the recombinant vaccine LYMErix in 1998; its manufacturer withdrew it from the market in 2002 amid concerns about side effects and declining sales. That history does not establish how LB6V will fare, but it is relevant to the public-health and commercial setting for a new candidate.
“Overall, I do think this vaccine has the potential to lower the Lyme disease burden.”
— Paul Auwaerter, MD, Johns Hopkins University School of Medicine, speaking at IDWeek
Questions on Duration and Trial Results
The reported results do not establish how the vaccine would perform in broader populations or how long meaningful protection lasts. The third-season efficacy estimate was 18.6%, but its confidence interval was extremely wide and included both negative and positive estimates. The available report also does not provide enough detail to determine why the modified intent-to-treat analysis differed from the evaluable-population analysis or how regulators may weigh each result.
It remains unclear whether LB6V will be submitted for regulatory review, whether additional analyses or studies are planned, and what dose schedule might ultimately be recommended. The suggestion of an annual booster came from Auwaerter; it is not a confirmed vaccination recommendation. The reported safety figures describe events during the trial and do not, on their own, settle the candidate’s overall benefit-risk assessment.
Further Review of LB6V Data
The next steps depend on the sponsor’s plans and any regulatory discussions, neither of which is specified in the source report. Further review will need to address the primary endpoint miss, the result from the modified analysis, safety findings, and the decline in protection indicators across seasons. Researchers may also investigate whether antibody measurements can help estimate protection in future studies, as Auwaerter suggested, but that possibility has not been established.
Until more information is available, LB6V remains investigational. The trial results do not change current prevention advice or provide a vaccine option for people at risk of tick bites. Any decision about development, booster timing or use would require further evidence and, if pursued, regulatory review.
Key Questions
Did LB6V pass its phase III trial?
Not in the main evaluable-population analysis. Its 73.2% efficacy estimate had a 95% confidence interval whose lower limit was 15.8%, below the trial’s required threshold of more than 20%. A modified intent-to-treat analysis narrowly cleared that cutoff.
How many Lyme disease cases occurred in the main analysis?
Four participants who received LB6V and 15 who received placebo developed Lyme disease in the evaluable population described in the report.
How long did protection appear to last?
Estimated efficacy was 73.2% in the second season and 18.6% in the third. The third-season confidence interval was very wide, so that estimate does not provide a precise measure of protection. The results raise questions about duration but do not establish a booster schedule.
Is there currently a Lyme disease vaccine available?
The source report says there are no currently available Lyme disease vaccines. LB6V is still an investigational candidate, and the trial results do not establish that it will be approved.
Source: medpagetoday.com
